Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema

PHASE2CompletedINTERVENTIONAL
Enrollment

302

Participants

Timeline

Start Date

March 2, 2016

Primary Completion Date

July 10, 2017

Study Completion Date

July 10, 2017

Conditions
Diabetic Macular Edema
Interventions
DRUG

REGN910-3

Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)

DRUG

Intravitreal Aflibercept Injection (IAI)

Trial Locations (51)

Unknown

Mesa

Tucson

Arcadia

Beverly Hills

Mountain View

Oceanside

Palm Desert

Colorado Springs

New London

Lakeland

Tampa

Winter Haven

Augusta

Decatur

‘Aiea

Chicago

New Albany

Shawnee Mission

Lexington

Portland

Baltimore

Rockville

Boston

Grand Rapids

Jackson

Minneapolis

Florissant

Las Vegas

Bloomfield

Edison

Teaneck

Albany

Rochester

Asheville

Charlotte

Kingston

Florence

West Columbia

Rapid City

Germantown

Nashville

Abilene

Austin

Dallas

Fort Worth

Harlingen

Houston

San Antonio

The Woodlands

Willow Park

Bellevue

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY